MUSC Hollings Cancer Center - Report to the Community 2026 - Flipbook - Page 11
Lung cancer
advances aren’t
reaching everyone
R
oughly half of older adults diagnosed with
metastatic non-small-cell lung cancer never
receive treatment, despite advances in options
over recent decades that have created meaningful
improvements in lifespan and quality of life for
many patients.
Although it’s dif昀椀cult to know how many were too sick to
be treated, a signi昀椀cant minority appeared to be suitable
candidates for treatment – meaning that people who
could possibly have had more good years with family and
friends simply didn’t receive the systemic therapies that
could have made that happen.
This startling reality was quanti昀椀ed and characterized
for the 昀椀rst time in a paper published May 7 in
JAMA Oncology.
Gerard Silvestri, M.D., and Adam Fox, M.D., both lung
cancer pulmonologists at MUSC Hollings Cancer Center,
led the study team on behalf of the American Cancer
Society National Lung Cancer Roundtable (ACS NLCRT).
“Lung cancer remains the leading cause of cancer-related
deaths in this country, with more Americans dying of
this disease than the next two cancer types combined,”
Silvestri said.
They noted that most of their oncologist colleagues
assume that most patients get treatment – and that’s
probably true for the patients who are referred to an
oncologist. But many patients never get that far.
The research highlights the importance of referring
patients to specialists who are familiar with the
latest treatments.
“The onus is on the medical community to
diagnose disease early, refer to an oncologist
quickly and recognize and communicate to
patients that there are available treatment
options that can improve both quality of life
and survival.”
Blood Cancer Journal
JAMA Network Open
A superantigen-based MHC class II-targeted cancer immunotherapy for the
treatment of acute myeloid leukemia
Medication samples and smoking cessation among adults: A randomized
clinical trial
Dolloff N, Ferreira LMR
Carpenter MJ, Dahne J, Gray KM, Kaczmar JM, Smith T, Toll BA
Report to the Community 2026 | 9